Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

被引:6
|
作者
Broadbent, Rachel [1 ,2 ]
Wheatley, Roseanna [1 ,2 ]
Stajer, Sabrina [3 ,4 ]
Jacobs, Timothy [2 ]
Lamarca, Angela [1 ,2 ]
Hubner, Richard A. [1 ,2 ]
Valle, Juan W. [1 ,2 ]
Amir, Eitan [3 ,4 ]
McNamara, Mairead G. [1 ,2 ]
机构
[1] Univ Manchester, Div Canc Sci, Manchester M20 4BX, Lancs, England
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[3] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
关键词
Gastroenteropancreatic; Neuroendocrine neoplasms; Resection; Relapse; Survival; SINGLE-INSTITUTION EXPERIENCE; LYMPH-NODE METASTASES; CURATIVE RESECTION; ADJUVANT THERAPY; FREE SURVIVAL; RISK-FACTORS; TUMORS; RECURRENCE; PREDICTORS; CLASSIFICATION;
D O I
10.1016/j.ctrv.2021.102299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastroenteropancreatic neoplasms (GEP-NENs) can potentially be cured through surgical resection, but only 42-57% achieve 5-year disease-free survival. There is a lack of consensus regarding the factors associated with relapse following resection of GEP-NENs. Methods: A systematic review identified studies reporting factors associated with relapse in patients with GEPNENs following resection of a primary tumour. Meta-analysis was performed to identify the factors prognostic for relapse-free survival (RFS) or overall survival (OS). Results: 63 studies comprising 13,715 patients were included; 56 studies reported on pancreatic NENs (12,418 patients), 24 reported on patients with grade 1-2 tumours (4,735 patients). Median follow-up was 44.2 months, median RFS was 32 months. Pooling of multivariable analyses of GEP-NENs (all sites and grades) found the following factors predicted worse RFS (all p values < 0.05): vascular resection performed, metastatic disease resected, grade 2 disease, grade 3 disease, tumour size > 20 mm, R1 resection, microvascular invasion, perineural invasion, Ki-67 > 5% and any lymph node positivity. In a subgroup of studies comprising exclusively of grade 1-2 GEP-NENs, R1 resection, perineural invasion, grade 2 disease, any lymph node positivity and tumour size > 20 mm predicted worse RFS (all p values < 0.05). Few OS data were available for pooling; in univariable analysis (entire cohort), grade 2 predicted worse OS (p = 0.007), while R1 resection did not (p = 0.14). Conclusions: The factors prognostic for worse RFS following resection of a GEP-NEN identified in this metaanalysis could be included in post-curative treatment surveillance clinical guidelines and inform the stratification and inclusion criteria of future adjuvant trials.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
    Broadbent, R.
    Wheatley, R.
    Stajer, S.
    Jacobs, T.
    Lamarca, A.
    Hubner, R.
    Valle, J.
    Amir, E.
    McNamara, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S114 - S114
  • [2] Prognostic value of inflammation-related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
    Cui, Ling-Jun
    Yu, Fu-Huan
    Cheng, Zi-Xuan
    Su, Fei
    Chen, Ying-Ying
    Tan, Huang-Ying
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 (04)
  • [3] Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis
    Leoncini, E.
    Carioli, G.
    La Vecchia, C.
    Boccia, S.
    Rindi, G.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 68 - 81
  • [4] Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
    Yan, Yu
    Wu, Danzhu
    Wang, Weizhen
    Lv, Yajuan
    Yang, Liyuan
    Liu, Yinglong
    Dong, Peng
    Yu, Xinshuang
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (02) : 633 - 641
  • [5] Prognostic factors in gastroenteropancreatic neuroendocrine neoplasms
    Zammouchi, A.
    Bennoui, R.
    Hammou, F. Hadj
    Moulai, N.
    Allal, S. Ahmed
    Ifaidi, G.
    Ouahioune, W.
    VIRCHOWS ARCHIV, 2024, 485 : S257 - S257
  • [6] Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis
    Ziogas, Ioannis A.
    Tasoudis, Panagiotis T.
    Borbon, Luis C.
    Sherman, Scott K.
    Breheny, Patrick J.
    Chandrasekharan, Chandrikha
    Dillon, Joseph S.
    Bellizzi, Andrew M.
    Howe, James R.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (01) : 148 - 160
  • [7] Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis
    Zhou, Yu
    Li, Dezhi
    Lin, Ye
    Yu, Min
    Lu, Xin
    Jian, Zhixiang
    Na, Ning
    Hou, Baohua
    ONCOTARGETS AND THERAPY, 2018, 11 : 2489 - 2496
  • [8] Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms
    Huang, Pao-Yuan
    Tsai, Kai-Lung
    Liang, Chih-Ming
    Tai, Wei-Chen
    Rau, Kun-Ming
    Wu, Keng-Liang
    Huang, Chao-Cheng
    Chuah, Seng-Kee
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (11): : 650 - 656
  • [9] Prognostic value of inflammation-related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP- NENs) - A systematic review and meta-analysis
    Yu, F. H.
    Cheng, Z. X.
    Su, F.
    Chen, Y. Y.
    Tan, H. Y.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 155 - 155
  • [10] Prognostic factors for resected cases with gallbladder carcinoma: a systematic review and meta-analysis
    Lv, Tian-Run
    Wang, Jun-Ke
    Li, Fu-Yu
    Hu, Hai-Jie
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (07) : 4342 - 4355